B cell activation factor (BAFF) is a novel adipokine that links obesity and inflammation |
| |
Authors: | Yu-Hee Kim Bong-Hyuk Choi Hyae-Gyeong Cheon Myoung-Sool Do |
| |
Affiliation: | 1School of Life and Food Sciences, Handong Global University, Pohang 791-708, Korea.;2Center for Metabolic Syndrome Therapeutics, Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon 305-343, Korea. |
| |
Abstract: | B cell activation factor (BAFF) is a novel member of the TNF ligand superfamily, mainly produced by myeloid cells. BAFF has been shown to participate in B-cell survival and B- and T-cell maturation. BAFF expression in adipocytes has been recently demonstrated. In the current study, we verified that BAFF expression is increased during adipocyte differentiation. BAFF expression was augmented by TNF-α treatment and was decreased by rosiglitazone treatment. BAFF secretion in lean and in ob/ob mice sera were compared and smaller amount of BAFF was secreted in ob/ob mice. mRNA and protein expression were different between epididymal and visceral adipose tissue. BAFF expression was also increased in ob/ob mouse adipose tissue. We sought to identify known BAFF receptors (BAFF-R, BCMA, and TACI) in adipocytes, and determined that all three were present and upregulated during adipocyte differentiation. However, the expression of TACI was distinct from that of BAFF-R and BCMA under TNF-α and BAFF ligand treatment. BAFF-R and BCMA expression levels were upregulated under pro-inflammatory conditions, but TACI was reduced. Conversely, BAFF-R and BCMA expression levels were downregulated by rosiglitazone treatment, but TACI was increased. Taken together, our results suggest that BAFF may be a new adipokine, representing a link between obesity and inflammation. |
| |
Keywords: | adipokine B-cell maturation antigen obesity rosiglitazone TNFRSF13C protein human TNFSF13B protein human transmembrane activator and CAML Interactor protein |
|
|